Coherus Oncology, Inc. (CHRS) Total liabilities 2016–2025
Coherus Oncology, Inc. (CHRS) total liabilities at each fiscal year-end, per SEC filings.
$197.3MFY2025 · since FY2016: $159.1M → $197.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $197.3M | -66.0% |
| FY2024 | $580.5M | -29.5% |
| FY2023 | $823.0M | +33.1% |
| FY2022 | $618.3M | +6.3% |
| FY2021 | $581.6M | +3.7% |
| FY2020 | $560.7M | +84.6% |
| FY2019 | $303.7M | +120.0% |
| FY2018 | $138.1M | +4.5% |
| FY2017 | $132.1M | -17.0% |
| FY2016 | $159.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CHRS financial trends
CHRS RevenueCHRS Net incomeCHRS Net marginCHRS Gross profitCHRS Gross marginCHRS Operating incomeCHRS Operating marginCHRS Operating cash flowCHRS Free cash flowCHRS Capital expendituresCHRS Return on equityCHRS Stock buybacksCHRS Dividends paidCHRS Total assetsCHRS Shareholders’ equityCHRS overview →